| Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans CJ Breitbach, J Burke, D Jonker, J Stephenson, AR Haas, LQM Chow, ... Nature 477 (7362), 99-102, 2011 | 625 | 2011 |
| The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers KA Parato, CJ Breitbach, F Le Boeuf, J Wang, C Storbeck, C Ilkow, ... Molecular Therapy 20 (4), 749-758, 2012 | 325 | 2012 |
| Targeting tumor vasculature with an oncolytic virus CJ Breitbach, NS De Silva, TJ Falls, U Aladl, L Evgin, J Paterson, YY Sun, ... Molecular Therapy 19 (5), 886-894, 2011 | 211 | 2011 |
| White paper on microbial anti-cancer therapy and prevention NS Forbes, RS Coffin, L Deng, L Evgin, S Fiering, M Giacalone, ... Journal for immunotherapy of cancer 6, 1-24, 2018 | 125 | 2018 |
| Oncolytic virus–mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice L Evgin, T Kottke, J Tonne, J Thompson, AL Huff, J van Vloten, M Moore, ... Science translational medicine 14 (640), eabn2231, 2022 | 84 | 2022 |
| Complement inhibition prevents oncolytic vaccinia virus neutralization in immune humans and cynomolgus macaques L Evgin, SA Acuna, CT De Souza, M Marguerie, CG Lemay, CS Ilkow, ... Molecular Therapy 23 (6), 1066-1076, 2015 | 80 | 2015 |
| Oncolytic virus-derived type I interferon restricts CAR T cell therapy L Evgin, AL Huff, P Wongthida, J Thompson, T Kottke, J Tonne, ... Nature communications 11 (1), 3187, 2020 | 77 | 2020 |
| Prime-boost using separate oncolytic viruses in combination with checkpoint blockade improves anti-tumour therapy E Ilett, T Kottke, J Thompson, K Rajani, S Zaidi, L Evgin, M Coffey, ... Gene therapy 24 (1), 21-30, 2017 | 75 | 2017 |
| APOBEC3B-mediated corruption of the tumor cell immunopeptidome induces heteroclitic neoepitopes for cancer immunotherapy CB Driscoll, MR Schuelke, T Kottke, JM Thompson, P Wongthida, ... Nature communications 11 (1), 790, 2020 | 55 | 2020 |
| Brain cancer induces systemic immunosuppression through release of non-steroid soluble mediators K Ayasoufi, CK Pfaller, L Evgin, RH Khadka, ZP Tritz, EN Goddery, ... Brain 143 (12), 3629-3652, 2020 | 47 | 2020 |
| Ad5NULL-A20: A Tropism-Modified, αvβ6 Integrin-Selective Oncolytic Adenovirus for Epithelial Ovarian Cancer Therapies H Uusi-Kerttula, JA Davies, JM Thompson, P Wongthida, L Evgin, ... Clinical Cancer Research 24 (17), 4215-4224, 2018 | 43 | 2018 |
| Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity L Evgin, M Vähä-Koskela, J Rintoul, T Falls, F Le Boeuf, JW Barrett, ... Molecular Therapy 18 (5), 896-902, 2010 | 40 | 2010 |
| Aptamer-facilitated protection of oncolytic virus from neutralizing antibodies D Muharemagic, A Zamay, SM Ghobadloo, L Evgin, A Savitskaya, JC Bell, ... Molecular therapy-Nucleic acids 3, 2014 | 39 | 2014 |
| Inhibitory receptors induced by VSV viroimmunotherapy are not necessarily targets for improving treatment efficacy KG Shim, S Zaidi, J Thompson, T Kottke, L Evgin, KR Rajani, M Schuelke, ... Molecular Therapy 25 (4), 962-975, 2017 | 32 | 2017 |
| Generation of a tumor-specific chemokine gradient using oncolytic vesicular stomatitis virus encoding CXCL9 EC Eckert, RA Nace, JM Tonne, L Evgin, RG Vile, SJ Russell Molecular Therapy-Oncolytics 16, 63-74, 2020 | 31 | 2020 |
| Subversion of NK-cell and TNFα immune surveillance drives tumor recurrence T Kottke, L Evgin, KG Shim, D Rommelfanger, N Boisgerault, S Zaidi, ... Cancer immunology research 5 (11), 1029-1045, 2017 | 26 | 2017 |
| APOBEC3 mediates resistance to oncolytic viral therapy AL Huff, P Wongthida, T Kottke, JM Thompson, CB Driscoll, M Schuelke, ... Molecular Therapy-Oncolytics 11, 1-13, 2018 | 25 | 2018 |
| Parking CAR T cells in tumours: oncolytic viruses as valets or vandals? L Evgin, RG Vile Cancers 13 (5), 1106, 2021 | 23 | 2021 |
| Diverse immunotherapies can effectively treat syngeneic brainstem tumors in the absence of overt toxicity MR Schuelke, P Wongthida, J Thompson, T Kottke, CB Driscoll, AL Huff, ... Journal for immunotherapy of cancer 7, 1-13, 2019 | 20 | 2019 |
| Suboptimal T-cell therapy drives a tumor cell mutator phenotype that promotes escape from first-line treatment L Evgin, AL Huff, T Kottke, J Thompson, AM Molan, CB Driscoll, ... Cancer immunology research 7 (5), 828-840, 2019 | 19 | 2019 |
